LIMN Liminatus Pharma LLC: Projected Price to Earnings

LIMN (Liminatus Pharma) - company brandmark

Liminatus Pharma (LIMN) forward P/E ratio exhibits volatility due to intense patent battles within the CAR-T therapy sector, where the metric stands at 0.00. Growth is driven by the co-financing of solid tumor research with biolabs. Development relies on private investments and the search for partners among academic centers to conduct clinical trials.

liminatuspharma.com - LIMN Future Price to Earnings Multiple (period 05/02/2025 - 11/16/2026)

Metric breakdowns and analytics for liminatuspharma.com (LIMN)

Fundamental company analysis:Liminatus Pharma Inc. LIMN
Signature product of Liminatus Pharma

Liminatus Pharma (LIMN) development of targeted CAR-T therapies against the GCC antigen in immuno-oncology determines the potential of the business's future cash flows. The company's expected P/E ratio compares the current market value of shares with projected net income, allowing investors to use this chart to assess the fairness of the asset's valuation and avoid value traps when analyzing the prospects for treating solid tumors.

Analysis of competing companies

Forward P/E Multiple IBRX|Immunocore Holdings plc (IMCR) - Forward Price to Earnings Multiple|Janux Therapeutics Inc - Projected Price to Earnings|Arcus Biosciences (RCUS) - Projected Price to Earnings Ratio|ZYME: Projected Price to Earnings|Future Price to Earnings Multiple TNGX (Tango Therapeutics, Inc.)|IOVA: Forward P/E Multiple|IMTX - Market Cap to Projected Earnings|Future Price to Earnings xencor.com|Projected Price to Earnings compasstherapeutics.com (CMPX)|Future Price to Earnings Replimune Group Inc (REPL)|Projected Price to Earnings Lyell Immunopharma Inc LYEL|Innate Pharma SA - Projected Price to Earnings|Forward P/E Multiple Pyxis Oncology, Inc. PYXS|CGEN - Future Price to Earnings|IOBT (iobiotech.com) - Price to Future Earnings Ratio|Sutro Biopharma, Inc (STRO) - Future Price to Earnings|Projected Price to Earnings Ratio MiNK (INKT)|Projected Price to Earnings HOWL|IMMX - Forward Price to Earnings Multiple|Projected Price to Earnings ALXO (ALX Oncology Holdings)|CUE (Cue Biopharma) - Future Price to Earnings Multiple|Forward P/E Multiple PDSB (PDS Biotechnology)|Future Price to Earnings Multiple SONN|MAIABiotech.com - Forward P/E Multiple|Projected Price to Earnings Ratio LAVA Therapeutics|NextCure, Inc. (NXTC) - Future Price to Earnings|Leap Therapeutics Inc - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple